




RealRate

PLASTIC & CHEMICALS 2024

Cyclo Therapeutics Inc
Rank 60 of 63





PLASTIC & CHEMICALS 2024

Cyclo Therapeutics Inc
Rank 60 of 63



The relative strengths and weaknesses of Cyclo Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyclo Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Cyclo Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 39%, being 82% points below the market average of 121%.

Input Variable	Value in 1000 USD
Assets, Current	12,318
Assets, Noncurrent	891
Cost of Revenues	0
Intangible Assets	0
Liabilities, Current	8,468
Liabilities, Noncurrent	22
Other Assets	0
Other Compr. Net Income	0
Other Expenses	6,945
Other Liabilities	0
Other Net Income	-7.2
Other Revenues	1,076
Property, Plant and Equipment, Net	38
Selling, General and Administrative Expense	14,182

Output Variable	Value in 1000 USD
Liabilities	8,491
Assets	13,248
Expenses	21,126
Revenues	1,076
Stockholders Equity	4,757
Net Income	-20,057
Comprehensive Net Income	-20,057
BaseVar	21,974
ECR before LimitedLiability	-149%
Economic Capital Ratio	39%